Iovance Biotherapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.

About IOVA

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. 

CEO
Frederick G. Vogt
CEOFrederick G. Vogt
Employees
975
Employees975
Headquarters
San Carlos, California
HeadquartersSan Carlos, California
Founded
2007
Founded2007
Employees
975
Employees975

IOVA Key Statistics

Market cap
1.41B
Market cap1.41B
Price-Earnings ratio
-3.06
Price-Earnings ratio-3.06
Dividend yield
Dividend yield
Average volume
10.89M
Average volume10.89M
High today
$3.51
High today$3.51
Low today
$3.32
Low today$3.32
Open price
$3.34
Open price$3.34
Volume
7.80M
Volume7.80M
52 Week high
$5.63
52 Week high$5.63
52 Week low
$1.64
52 Week low$1.64

Stock Snapshot

As of today, Iovance Biotherapeutics(IOVA) shares are valued at $3.42. The company's market cap stands at 1.41B, with a P/E ratio of -3.06.

On 2026-04-03, Iovance Biotherapeutics(IOVA) stock moved within a range of $3.32 to $3.51. With shares now at $3.42, the stock is trading +3.0% above its intraday low and -2.4% below the session's peak.

Trading activity shows a volume of 7.8M, compared to an average daily volume of 10.89M.

The stock's 52-week range extends from a low of $1.64 to a high of $5.63.

The stock's 52-week range extends from a low of $1.64 to a high of $5.63.

IOVA News

Simply Wall St 14h
Iovance Biotherapeutics Is Down 6.5% After FDA Questions Amtagvi Marketing Claims Has The Bull Case Changed?

In March 2026, the FDA’s Center for Biologics Evaluation and Research issued an untitled letter to Iovance Biotherapeutics over Amtagvi promotional materials, c...

Iovance Biotherapeutics Is Down 6.5% After FDA Questions Amtagvi Marketing Claims Has The Bull Case Changed?

Analyst ratings

73%

of 11 ratings
Buy
72.7%
Hold
27.3%
Sell
0%

People also own

Based on the portfolios of people who own IOVA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.